Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) jumped 5.05% in pre-market trading on Thursday, following the release of positive Phase 2 data for its lead drug candidate REC-994 in treating cerebral cavernous malformations (CCM).
The company reported that in the Phase 2 SYCAMORE study, REC-994 met the primary endpoint of safety and tolerability, with no treatment-related discontinuations or Grade 3 adverse events. More importantly, the 400mg dose showed promising trends in reducing total lesion volume and improving functional outcomes as measured by the modified Rankin Scale (mRS). These positive signals were observed in both the overall study population and the subset of patients with brainstem lesions, representing a high unmet medical need.
Based on these encouraging results, Recursion plans to submit the data for publication in a peer-reviewed journal and engage in regulatory discussions on the next development steps for REC-994. The company also has an ongoing long-term extension study to gather additional data on REC-994's efficacy and safety profile.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。